S Delaloge
Overview
Explore the profile of S Delaloge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
2767
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Metzger Filho O, Cardoso F, Poncet C, Desmedt C, Linn S, Wesseling J, et al.
Eur J Cancer
. 2025 Jan;
217:115222.
PMID: 39864363
Background: Evaluation of the prognostic performance and clinical utility of the MammaPrint 70-gene signature in early-stage invasive lobular carcinoma (ILC) for whom such analyses in a randomized trial is awaited....
2.
Prelaj A, Miskovic V, Zanitti M, Trovo F, Genova C, Viscardi G, et al.
Ann Oncol
. 2023 Oct;
35(1):29-65.
PMID: 37879443
Background: The widespread use of immune checkpoint inhibitors (ICIs) has revolutionised treatment of multiple cancer types. However, selecting patients who may benefit from ICI remains challenging. Artificial intelligence (AI) approaches...
3.
Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen J, Suijkerbuijk K, et al.
Ann Oncol
. 2023 Oct;
34(12):1097-1112.
PMID: 37848160
No abstract available.
4.
Frenel J, Lusque A, Delaloge S, Ferrero J, Bachelot T, Desmoulins I, et al.
Br J Cancer
. 2023 Apr;
128(11):2072-2080.
PMID: 37012318
Background: Efficacy of endocrine therapy in HR+/HER2- metastatic breast cancer could differ depending on the presence of BRCA1/2 germline mutation. Methods: The ESME metastatic breast cancer platform (NCT03275311) is a...
5.
Veron L, Chaltiel D, Raynard B, Rassy N, Scotte F, Charles C, et al.
Clin Nutr ESPEN
. 2023 Mar;
54:421-429.
PMID: 36963889
Background & Aims: Nutrition is one of the fundamentals of cancer prevention. Knowing what are the patients' needs and beliefs in terms of "nutrition and cancer" information helps tailor future...
6.
Bello Roufai D, Goncalves A, de La Motte Rouge T, Akla S, Blonz C, Grenier J, et al.
Oncogene
. 2023 Mar;
42(17):1417.
PMID: 36922682
No abstract available.
7.
Bello Roufai D, Goncalves A, de La Motte Rouge T, Akla S, Blonz C, Grenier J, et al.
Oncogene
. 2023 Jan;
42(23):1951-1956.
PMID: 36611120
SOLAR-1 and BYLieve trials documented the efficacy of the PI3K-inhibitor alpelisib in pre-treated PIK3CA-mutant, hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer (ABC) patients. We report here real-life data of patients...
8.
Geyer Jr C, Garber J, Gelber R, Yothers G, Taboada M, Ross L, et al.
Ann Oncol
. 2022 Oct;
33(12):1250-1268.
PMID: 36228963
Background: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic...
9.
Wuerstlein R, Ellis P, Montemurro F, Torres A, Delaloge S, Zhang Q, et al.
ESMO Open
. 2022 Sep;
7(5):100561.
PMID: 36084395
Background: KAMILLA is a single-arm safety study of trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (BC; NCT01702571). We report the final...
10.
Trapani D, Franzoi M, Burstein H, Carey L, Delaloge S, Harbeck N, et al.
Ann Oncol
. 2022 May;
33(7):702-712.
PMID: 35550723
Background: The landscape of clinical trials testing risk-adapted modulations of cancer treatments is complex. Multiple trial designs, endpoints, and thresholds for non-inferiority have been used; however, no consensus or convention...